SPIRITT: A study of second-line treatment of metastatic colorectal cancer with FOLFIRI plus panitumumab or bevacizumab

Community Oncology

Volumn 5, Issue 11 SUPPL. B, 2008, Pages 1-4

  Hecht, J Randolph ^a,c   Cohn, Allen L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Rocky Mountain Cancer Center   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; SKIN PROTECTIVE AGENT; STEROID; SUNSCREEN;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DRUG BINDING; DRUG HYPERSENSITIVITY; DRUG INFUSION REACTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; FATIGUE; GENE MUTATION; HAIR DISEASE; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPOMAGNESEMIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; RASH; SIDE EFFECT; SKIN FISSURE; SKIN MANIFESTATION; SKIN TOXICITY; TELANGIECTASIA; TREATMENT OUTCOME; VOMITING;

EID: 57149106536     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
2. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxalilatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Grávalos C, Cassinello J, Fernández-Rañada I, Holgado E. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer 2007;6:691-699.
5. Grothey A. The continuum of care in colorectal cancer: eliminating the concept of distinct lines of treatment. 2007 American Society of Clinical Oncology Education Book. Alexandria, Va: American Society of Clinical Oncology; 2007:224-228.
6. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
7. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
9. Cartenì G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C. Panitumumab a novel drug in cancer treatment. Ann Oncol 2007;18(suppl 6):vi16-21.
10. Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008;14:502-508.
11. Wirth LJ, Posner MR, Tishler RB, et al. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol 2008;26(15S):6007.
12. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
13. Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGER) levels: an updated analysis. J Clin Oncol 2007;25 (18S):4082.
14. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
15. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007;18:7-15.
16. Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006;66:2005-2014.
17. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-988.
18. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:427-432.
19. Siena S, Tabernero J, Burkes RL, et al. Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. J Clin Oncol 2008;26(15S):4034.
20. Peeters M, Wilson G, Ducreux M, et al. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results. J Clin Oncol 2008;26(15S):4064.
21. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008;26(15S):2.
22. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
23. Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008;7:184-190.
24. Hecht JR, Mitchell EP, Baranda J, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGER): final efficacy and KRAS analyses. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Fla. Abstract 343.
25. th World Congress on Gastrointestinal Cancer; June 25-28, 2008; Barcelona, Spain.